SLC5A2 and metabolic dysfunction-associated steatohepatitis: Therefore, in this study, using a medaka NASH model, we investigated the effect of the Tofo, which has a higher specificity in inhibiting SGLT2 23, on the NASH liver to obtain new insights on the time‐dependent effects of Tofo treatment and extensive quantitative changes in the liver histology and disease parameters, because in this model, we could maintain the serum concentration of the medicine by keeping them in the water of the averaged concentrated with medicines.